X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the new agreement, Acer will reacquire worldwide development, commercialization and economic rights to OLPRUVA™ (sodium phenylbutyrate) from Relief Therapeutics, excluding the European Union. OLPRUVA™ is approved in the U.S. for treatment of UCDs.
Lead Product(s): Sodium Phenylbutyrate
Therapeutic Area: Genetic Disease Product Name: Olpruva
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Acer Therapeutics
Deal Size: $56.5 million Upfront Cash: $11.5 million
Deal Type: Licensing Agreement August 30, 2023
Details:
Olpruva (sodium phenylbutyrate) active metabolite is phenylacetate which conjugates with glutamine to form phenylacetylglutamine. Phenylacetylglutamine is excreted by the kidneys, hence providing an alternate vehicle for waste nitrogen excretion.
Lead Product(s): Sodium Phenylbutyrate
Therapeutic Area: Genetic Disease Product Name: Olpruva
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Acer Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
RLF-100® (aviptadil acetate) restores barrier function at the endothelial/alveolar interface and thereby protects the lung and other organs from failure. It is under development for the potential treatment of acute and chronic lung disease.
Lead Product(s): Aviptadil Acetate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RLF-100
Highest Development Status: Phase II/ Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
Olpruva (sodium phenylbutyrate)active metabolite is phenylacetate which conjugates with glutamine to form phenylacetylglutamine. Phenylacetylglutamine is excreted by the kidneys, hence providing an alternate vehicle for waste nitrogen excretion.
Lead Product(s): Sodium Phenylbutyrate
Therapeutic Area: Genetic Disease Product Name: Olpruva
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Acer Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2023
Details:
RLF-TD011 is a differentiated acid oxidizing solution of hypochlorous acid which shows antimicrobial action with anti-inflammatory properties, allowing infection control, reduction of wound colonization, alleviation of pain and itching and improved wound healing.
Lead Product(s): RLF-TD011
Therapeutic Area: Rare Diseases and Disorders Product Name: Nexodyn
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
OLPRUVA™ (sodium phenylbutyrate), is an oral suspension prescription medicine used for the treatment of rare, genetic disorders like Urea cycle disorders (UCDs) .
Lead Product(s): Sodium Phenylbutyrate
Therapeutic Area: Genetic Disease Product Name: Olpruva
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Acer Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2022
Details:
Zyesami (aviptadil acetate) is an inhaled formulation of synthetic human Vasoactive Intestinal Polypeptide (VIP) in development for the treatment of patients with critical COVID-19 respiratory failure.
Lead Product(s): Aviptadil Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: Zyesami
Highest Development Status: Phase IIIProduct Type: Peptide
Recipient: NRx Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 19, 2022
Details:
APR-TD011 has potential for the treatment of wounds in epidermolysis bullosa ("EB"), a group of rare, genetic, life-threatening connective tissue disorders characterized by fragile skin and mucous membrane with severe blistering throughout the body.
Lead Product(s): Aviptadil Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: Zyesami
Highest Development Status: Phase IIIProduct Type: Peptide
Recipient: NRx Pharmaceuticals
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Agreement November 14, 2022
Details:
RLF-100® (aviptadil) is a synthetic form of Vasoactive Intestinal Peptide (“VIP”) consisting of 28 amino acids. The reported data demonstrated high purity levels at six months at all temperatures tested, including at refrigerated and room temperature environments.
Lead Product(s): Aviptadil Acetate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RLF-100
Highest Development Status: Phase II/ Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
PKU GOLIKE® - a next generation medical phenylalanine-free food product engineered with the patent protected, pharmaceutical grade Physiomimic™ technology for the dietary management of phenylketonuria (PKU).
Lead Product(s): Amino Acids Mixture
Therapeutic Area: Genetic Disease Product Name: PKU GOLIKE
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
